Spyre Therapeutics, Inc. — Form 10-Q
Filed November 3, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 22/100
What the filing says
Spyre Therapeutics filed amended corporate documents on October 29, 2026, correcting its Certificate of Incorporation to reinstate omitted preferred stock designations (Series A: 1,086,341 shares at 1,000:1 conversion ratio; Series B: 271,625 shares at 40:1 ratio, later eliminated via Certificate of Elimination). Concurrently, three executive employment agreements were amended effective November 2, 2026: CEO Cameron Turtle ($695K base, 60% target bonus, 24-month CIC severance of 2.0× base + bonus); CFO Scott Burrows ($510K base, 40% target bonus, 18-month CIC severance of 1.5×); and CLO Heidy King-Jones ($510K base, 40% target bonus, 18-month CIC severance of 1.5×). No dollar amounts, dates, or share counts for actual issuances or transactions are disclosed in the filing—only authorized amounts and agreement terms.
Why this rating
Filing corrects administrative omissions and updates executive agreements, both routine for $1.1B company. No material transaction, equity issuance, or business change disclosed—boilerplate governance and compensation restatement.
See more from November 3, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.